TOP > R&D INFORMATION > Priority Development Projects
R&D INFORMATION

Priority Development Projects

Concentration of Company’s Resources on Priority Projects

The supreme mission of a pharmaceutical maker is to create innovative drugs, which can fulfil unmet medical needs, and to then provide them to patients around the world as soon as possible.Our R&D Division aims to create first-in-class and best-in-class drugs with high added value that contribute to public health by expanding its accumulated pharmaceutical technology for the development of innovative, high-quality drugs.Providing drugs urgently awaited by patients and medical professionals around the world is DAIICHI SANKYO’s strongest desire.

Making New Drugs Available to Patients Worldwide as Soon as Possible

DAIICHI SANKYO conducts prioritization assessment of development pipelines through its top decision-making body, GEMRAD.
Currently, the following four projects are being pursued as priority projects. We hope to accelerate their development through the prioritized allocation of our Company’s resources.

Prasugrel (CS-747) Edoxaban (DU-176b) Denosumab (AMG 162)